Research Progress on the Treatment of Qi Deficiency and Blood Stasis Type Hand-foot Syndrome by Buyang Huanwu Decoction

Author:

Qu Jianmin,Wang Gang

Abstract

Hand-foot syndrome (HFS) is one of the common adverse reactions in the treatment of malignant tumors, and its incidence is gradually increasing with the widespread use of antitumor drugs. HFS seriously affects patients' daily social and life, and even leads to drug dosage reduction or early discontinuation of medication, which delays treatment. Modern medicine has not yet fully clarified the understanding of its etiology and pathogenesis, the lack of uniform standards for the evaluation of therapeutic efficacy, and the poor effect of targeted systemic therapy. Chinese medicine classifies HFS into the category of "blood paralysis", and considers that the disease is located in the hands and feet, with deficiency as the main cause, and the deficiency as the underlying cause, and the mixture of deficiency and reality. BHD is from the book "Reform and Error Correction of Medical Forests" written by Qing Dynasty physician Wang Qingren, which has the effects of tonifying qi, activating blood and clearing collaterals. The formula is rigorous and well formulated, and is now widely used in all kinds of diseases with qi deficiency and blood stasis, with remarkable results. In recent years, with the rapid development of modern pharmacology, the research on the microscopic mechanism of action of BHD has been developing and deepening, which provides new ideas for the treatment of the disease. In this paper, we review BHD in HFS in the treatment of malignant tumors from the aspects of its formula and modern pharmacological research, with a view to providing clinical basis and reference for the future treatment of HFS of qi deficiency and blood stasis type by BHD.

Publisher

Century Science Publishing Co

Reference39 articles.

1. XI Chenxi, QIANG Wanmin, WANG Shurui, et al. Current status and research progress in the management of chemotherapy-induced hand-foot syndrome[J]. Nursing and Rehabilitation, 2023, 22(05):94-97.

2. Chen J, Wang Z. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs[J]. Journal of Oncology Pharmacy Practice, 2021, 27(4): 919-929.

3. LIU Shujuan, WANG Wei. Progress in the study of immunoinflammatory mechanism of peripheral neuropathy caused by paclitaxel[J]. Shaanxi Medical Journal, 2022, 51(04):511-513.

4. Takahashi Y, Takei Y, Machida S, et al. Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine[J]. Journal of Obstetrics and Gynaecology Research, 2021, 47(2): 551-559.

5. Kuji M, Masuko H, Yamagami H, et al. Adjuvant chemotherapy with capecitabine for colon cancer-a case series[J]. Gan to Kagaku ryoho. Cancer & Chemotherapy, 2014, 41(12): 1752-1754.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3